# Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma

> **NCT00005580** · PHASE1 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 54 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** bryostatin 1
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00005580
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2010-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005580, "Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00005580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*